{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-010227","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.175980+00:00","generated_at":"2026-06-06T08:32:17.148202+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"PBAX amends merger agreement with CERo, secures $2M PIPE, and target qualifies for potential $4-6M grant","bullets":["Amendment to BCA removes minimum cash condition, resets earnout price targets based on Series A conversion price, and increases shares issuable to CERo stockholders from ~4.65M to 5.0M shares.","PIPE financing of $2.0M from accredited investor in exchange for Series A Preferred Stock and warrants to purchase 125,000 shares; closing contingent on business combination.","CERo selected as finalist for $4-6M subsidized grant from Cancer Focus Fund at MD Anderson for CER-1236 trial in AML; grant is not assured.","PIPE securities issued in reliance on Section 4(a)(2) and Rule 506 of Regulation D; not registered under Securities Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-010227","json":"https://secwatch.observer/filing/0001213900-24-010227.json","markdown":"https://secwatch.observer/filing/0001213900-24-010227.md","text":"https://secwatch.observer/filing/0001213900-24-010227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/ea192779-8k425_phoenix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:32:17.148202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50b72a9f8d24edf9f26d7643c06d3e0b25ee0ea1","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Securities Purchase Agreement with an accredited investor valued at $2.0 million (effective 2024-02-05).","evidence_excerpt":"On February 5, 2024, the Company entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2.0 million"},{"label":"Effective","value":"2024-02-05"}],"fact_type":"material_agreement"},{"claim_id":"dd79d2d375d9bf664fceb83a93cc06341b6e882b","claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Amendment No. 1 to the Business Combination Agreement with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc. (effective 2024-02-05).","evidence_excerpt":"arties entered into Amendment No. 1 to the Business Combination Agreement (the “ Amendment ”) to, among other things, (i) remove the minimum cash condition, (ii) modify the stock-price based milestones such that (a) the trading price condition for the","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024010227/0001213900-24-010227-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc. and CERo Therapeutics, Inc."},{"label":"Effective","value":"2024-02-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}